220 related articles for article (PubMed ID: 23307977)
1. Multiple myeloma, version 1.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
[TBL] [Abstract][Full Text] [Related]
2. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
[No Abstract] [Full Text] [Related]
3. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
4. [Carfilzomib in multiple myeloma relapses].
Bay JO
Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
[No Abstract] [Full Text] [Related]
5. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Fenk R; Michael M; Zohren F; Graef T; Czibere A; Bruns I; Neumann F; Fenk B; Haas R; Kobbe G
Leuk Lymphoma; 2007 Dec; 48(12):2345-51. PubMed ID: 18067009
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine: the remedy that came in from the cold.
Lentzsch S
Blood; 2014 Feb; 123(7):948-50. PubMed ID: 24526773
[No Abstract] [Full Text] [Related]
7. What is the correct philosophy for the treatment of multiple myeloma?
Gertz MA
Leuk Lymphoma; 2007 Dec; 48(12):2298-9. PubMed ID: 18066999
[No Abstract] [Full Text] [Related]
8. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
9. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Takeda Y; Sakaida E; Nakaseko C
Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
13. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
[No Abstract] [Full Text] [Related]
15. "IM iD"eally treating multiple myeloma.
Lacy MQ
Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
[TBL] [Abstract][Full Text] [Related]
16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
17. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
20. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
